Chief executive officer Pascal Soriot also described the data from the AstraZeneca lung cancer drug trial as statistically positive.
The drugmaker’s shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called Tropion-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media today after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further.
Nigeria Nigeria Latest News, Nigeria Nigeria Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: staronline - 🏆 4. / 75 Read more »